These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15946843)

  • 41. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
    Todorovic C; Jahn O; Tezval H; Hippel C; Spiess J
    Neurosci Biobehav Rev; 2005; 29(8):1323-33. PubMed ID: 16099044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.
    Molteni V; Penzotti J; Wilson DM; Termin AP; Mao L; Crane CM; Hassman F; Wang T; Wong H; Miller KJ; Grossman S; Grootenhuis PD
    J Med Chem; 2004 May; 47(10):2426-9. PubMed ID: 15115386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF₁) receptor antagonists.
    Ahuja VT; Hartz RA; Molski TF; Mattson GK; Lentz KA; Grace JE; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2016 May; 26(9):2184-7. PubMed ID: 27020524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and structure-activity relationships of 5-alkylaminolquinolines as a novel series of CRF1 receptor antagonists.
    Takeda K; Terauchi T; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4756-61. PubMed ID: 22683343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists.
    Dzierba CD; Sielecki TM; Arvanitis AG; Galka A; Johnson TL; Takvorian AG; Rafalski M; Kasireddy-Polam P; Vig S; Dasgupta B; Zhang G; Molski TF; Wong H; Zaczek RC; Lodge NJ; Combs AP; Gilligan PJ; Trainor GL; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2012 Aug; 22(15):4986-9. PubMed ID: 22749422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The therapeutic potential of CRF1 antagonists for anxiety.
    Zorrilla EP; Koob GF
    Expert Opin Investig Drugs; 2004 Jul; 13(7):799-828. PubMed ID: 15212620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Hartz RA; Ahuja VT; Zhuo X; Mattson RJ; Denhart DJ; Deskus JA; Vrudhula VM; Pan S; Ditta JL; Shu YZ; Grace JE; Lentz KA; Lelas S; Li YW; Molski TF; Krishnananthan S; Wong H; Qian-Cutrone J; Schartman R; Denton R; Lodge NJ; Zaczek R; Macor JE; Bronson JJ
    J Med Chem; 2009 Dec; 52(23):7653-68. PubMed ID: 19954247
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of CP 154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats.
    Przegaliński E; Filip M; Frankowska M; Zaniewska M; Papla I
    Neuropeptides; 2005 Oct; 39(5):525-33. PubMed ID: 16139885
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F; Ising M
    Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antidepressant efficacy screening of novel targets in the chick anxiety-depression model.
    Sufka KJ; Warnick JE; Pulaski CN; Slauson SR; Kim YB; Rimoldi JM
    Behav Pharmacol; 2009 Mar; 20(2):146-54. PubMed ID: 19300238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.
    Drabczyńska A; Müller CE; Schiedel A; Schumacher B; Karolak-Wojciechowska J; Fruziński A; Zobnina W; Yuzlenko O; Kieć-Kononowicz K
    Bioorg Med Chem; 2007 Nov; 15(22):6956-74. PubMed ID: 17827019
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
    Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
    Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor.
    Hoare SR; Brown BT; Santos MA; Malany S; Betz SF; Grigoriadis DE
    Biochem Pharmacol; 2006 Jul; 72(2):244-55. PubMed ID: 16750175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists.
    Guo Z; Wu D; Zhu YF; Tucci FC; Regan CF; Rowbottom MW; Struthers RS; Xie Q; Reijmers S; Sullivan SK; Sai Y; Chen C
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3685-90. PubMed ID: 15951171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
    Huang CQ; Wilcoxen K; McCarthy JR; Haddach M; Webb TR; Gu J; Xie YF; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3375-9. PubMed ID: 12951129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists.
    Zuev D; Vrudhula VM; Michne JA; Dasgupta B; Pin SS; Huang XS; Wu D; Gao Q; Zhang J; Taber MT; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3669-74. PubMed ID: 20471832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dihydropyridopyrazinones and dihydropteridinones as corticotropin-releasing factor-1 receptor antagonists: structure-activity relationships and computational modeling.
    Dzierba CD; Tebben AJ; Wilde RG; Takvorian AG; Rafalski M; Kasireddy-Polam P; Klaczkiewicz JD; Pechulis AD; Davis AL; Sweet MP; Woo AM; Yang Z; Ebeltoft SM; Molski TF; Zhang G; Zaczek RC; Trainor GL; Combs AP; Gilligan PJ
    J Med Chem; 2007 May; 50(9):2269-72. PubMed ID: 17402721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists.
    Nakazato A; Kumagai T; Okubo T; Tanaka H; Chaki S; Okuyama S; Tomisawa K
    Bioorg Med Chem; 2000 May; 8(5):1183-93. PubMed ID: 10882028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A; Stachowicz K; Tatarczyńska E
    Neuropharmacology; 2006 Sep; 51(3):578-86. PubMed ID: 16828124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The CRF1 receptor antagonist, antalarmin, reverses isolation-induced up-regulation of dopamine D2 receptors in the amygdala and nucleus accumbens of fawn-hooded rats.
    Djouma E; Card K; Lodge DJ; Lawrence AJ
    Eur J Neurosci; 2006 Jun; 23(12):3319-27. PubMed ID: 16820021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.